NASDAQ:AKBA - Akebia Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.78 +0.05 (+0.65 %)
(As of 11/14/2018 06:56 AM ET)
Previous Close$7.73
Today's Range$7.72 - $8.24
52-Week Range$7.32 - $16.43
Volume560,900 shs
Average Volume600,066 shs
Market Capitalization$441.07 million
P/E Ratio-4.40
Dividend YieldN/A
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients. The company is also developing a HIF-based portfolio of product candidates, such as AKB-5169, a preclinical compound for the treatment of inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds internationally. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Receive AKBA News and Ratings via Email

Sign-up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Current SymbolNASDAQ:AKBA
Previous Symbol


Debt-to-Equity RatioN/A
Current Ratio2.24
Quick Ratio2.24


Trailing P/E Ratio-4.40
Forward P/E Ratio-2.88
P/E GrowthN/A

Sales & Book Value

Annual Sales$177.98 million
Price / Sales2.49
Cash FlowN/A
Price / CashN/A
Book Value$2.50 per share
Price / Book3.11


EPS (Most Recent Fiscal Year)($1.77)
Net Income$-76,910,000.00
Net Margins-30.29%
Return on Equity-45.61%
Return on Assets-17.54%


Outstanding Shares57,060,000
Market Cap$441.07 million

Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions

What is Akebia Therapeutics' stock symbol?

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics Inc (NASDAQ:AKBA) announced its quarterly earnings data on Thursday, November, 8th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.64) by $0.18. The biopharmaceutical company had revenue of $53.17 million for the quarter, compared to analysts' expectations of $39.71 million. Akebia Therapeutics had a negative net margin of 30.29% and a negative return on equity of 45.61%. View Akebia Therapeutics' Earnings History.

When is Akebia Therapeutics' next earnings date?

Akebia Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Akebia Therapeutics.

What price target have analysts set for AKBA?

7 equities research analysts have issued 12 month target prices for Akebia Therapeutics' stock. Their forecasts range from $9.00 to $30.00. On average, they expect Akebia Therapeutics' share price to reach $20.00 in the next twelve months. This suggests a possible upside of 157.1% from the stock's current price. View Analyst Price Targets for Akebia Therapeutics.

What is the consensus analysts' recommendation for Akebia Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akebia Therapeutics.

What are Wall Street analysts saying about Akebia Therapeutics stock?

Here are some recent quotes from research analysts about Akebia Therapeutics stock:
  • 1. According to Zacks Investment Research, "Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (10/10/2018)
  • 2. HC Wainwright analysts commented, "Our $42 price target is based on a 13-year DCF analysis of the Hemophilia B (65% (5% POS). We anticipate Hemophilia B commercial launch during 2021 and model risk-adjusted peak sales of roughly $820M during 2028. We assume a launch price of $772.5K (durability >5 years), and at peak, we estimate about 775 patients in the U.S. and approximately 1,050 patients in the developed markets who would have received uniQure’s gene therapy, which represents an 50% of the overall commercial opportunity." (6/29/2018)
  • 3. Mizuho analysts commented, "We had a chance to catch up with CEO John Butler yesterday at the Bio CEO & Investor Conference. We summarize our key takeaways below. Akebia also provided an update on the Vadadustat development program yesterday morning including an expansion of the ongoing phase 2 For2ward and phase 3 Trilo2gy trials in collaboration with Otsuka (TYO:4578, Non rated). While this will delay the timeline for topline data in both programs, we see it as a positive overall as the company will now incorporate additional relevant endpoints with a greater number of patients for better positioning in commercialization. The timeline for data-readouts in the two pivotal Pro2tect and Inno2vate trials remains unchanged." (2/13/2018)

Has Akebia Therapeutics been receiving favorable news coverage?

Media stories about AKBA stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Akebia Therapeutics earned a daily sentiment score of -1.7 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the near future.

Who are some of Akebia Therapeutics' key competitors?

Who are Akebia Therapeutics' key executives?

Akebia Therapeutics' management team includes the folowing people:
  • Mr. John P. Butler, CEO, Pres & Director (Age 54)
  • Mr. Michel Dahan, Sr. VP & Chief Bus. Officer (Age 39)
  • Dr. Rita Jain, Sr. VP & Chief Medical Officer (Age 56)
  • Mr. Jason A. Amello, Sr. VP, CFO & Treasurer (Age 50)
  • Ms. Theresa McNeely, Sr. VP - Corp. Communications and Investor Relations (Age 54)

Who are Akebia Therapeutics' major shareholders?

Akebia Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.23%), Renaissance Technologies LLC (3.11%), Abrams Capital Management L.P. (1.96%), First Manhattan Co. (1.40%), FMR LLC (1.18%) and Dimensional Fund Advisors LP (0.80%). Company insiders that own Akebia Therapeutics stock include Duane Nash, Michel Dahan, Muneer A Satter and Nicole R Hadas. View Institutional Ownership Trends for Akebia Therapeutics.

Which major investors are selling Akebia Therapeutics stock?

AKBA stock was sold by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, Alambic Investment Management L.P., FMR LLC, Los Angeles Capital Management & Equity Research Inc., Renaissance Technologies LLC, Wells Fargo & Company MN, Stanley Laman Group Ltd. and Acadian Asset Management LLC. View Insider Buying and Selling for Akebia Therapeutics.

Which major investors are buying Akebia Therapeutics stock?

AKBA stock was purchased by a variety of institutional investors in the last quarter, including Abrams Capital Management L.P., Dimensional Fund Advisors LP, Rubric Capital Management LP, BlackRock Inc., First Manhattan Co., SG Americas Securities LLC, Candriam Luxembourg S.C.A. and Rice Hall James & Associates LLC. View Insider Buying and Selling for Akebia Therapeutics.

How do I buy shares of Akebia Therapeutics?

Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Akebia Therapeutics' stock price today?

One share of AKBA stock can currently be purchased for approximately $7.78.

How big of a company is Akebia Therapeutics?

Akebia Therapeutics has a market capitalization of $441.07 million and generates $177.98 million in revenue each year. The biopharmaceutical company earns $-76,910,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. Akebia Therapeutics employs 114 workers across the globe.

What is Akebia Therapeutics' official website?

The official website for Akebia Therapeutics is

How can I contact Akebia Therapeutics?

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]

MarketBeat Community Rating for Akebia Therapeutics (NASDAQ AKBA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  271 (Vote Outperform)
Underperform Votes:  196 (Vote Underperform)
Total Votes:  467
MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. Vote "Outperform" if you believe AKBA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKBA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/14/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel